07:51 AM EDT, 10/09/2024 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Wednesday that its oncology drug candidate Namodenoson, whihc treats pancreatic cancer, has received Orphan Drug Designation from the US Food and Drug Administration.

The company said it is now finalizing all preparatory requirements for a mid-stage trial in participants suffering from pancreatic cancer to evaluate the safety, clinical activity, and pharmacokinetics of Namodenoson.

Can-Fite said it will enroll 20 patients in the trial, which it plans to start by the end of this year.

Price: 2.1500, Change: +0.11, Percent Change: +5.39